Tabovi (adalimumab biosimilar)
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
(clinicaltrials.gov)
- P4 | N=30 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: May 2026 ➔ Aug 2026
Enrollment open • Trial initiation date • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1